(GEHC) GE HealthCare Technologies - NASDAQ
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 28.017m USD | Total Return: -12% in 12m
Avg Turnover: 304M
EPS Trend: 80.1%
Qual. Beats: 0
Rev. Trend: 82.8%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality
GE HealthCare Technologies Inc. (NASDAQ: GEHC) is a U.S.-based medical technology company that develops, manufactures, and markets diagnostic imaging, patient care, and pharmaceutical diagnostic products, services, and digital solutions. Spun off from General Electric in early 2023, the company is headquartered in Chicago and operates in the U.S., Canada, and international markets.
The business is organized into four segments: Imaging (CT, MR, X-ray, molecular imaging, and womens health), Advanced Visualization Solutions (ultrasound, image-guided therapies, and surgical visualization), Patient Care Solutions (monitoring, diagnostic cardiology, anesthesia, and maternal infant care), and Pharmaceutical Diagnostics (contrast media and radiopharmaceuticals for radiology and nuclear medicine). The PDx segment supplies diagnostic agents used to enhance tissue visibility during imaging exams, and the company maintains a strategic collaboration with DeepHealth.
Within the health care equipment industry, GE HealthCare competes in a concentrated global market alongside other major imaging and diagnostic equipment manufacturers, where scale, installed-base service revenue, and recurring consumables and radiopharmaceutical sales typically drive margin performance.
- Imaging orders rebound as hospital capital spending recovers
- Contrast media supply tightness lifts Pharmaceutical Diagnostics margins
- Buyback execution supports earnings amid Siemens and Philips competition
| Net Income: 1.50b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.00 > 1.0 |
| NWC/Revenue: 7.28% < 20% (prev -3.00%; Δ 10.27% < -1%) |
| CFO/TA 0.05 > 3% & CFO 2.03b > Net Income 1.50b |
| Net Debt (8.73b) to EBITDA (3.40b): 2.57 < 3 |
| Current Ratio: 1.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (457.0m) vs 12m ago -0.44% < -2% |
| Gross Margin: 42.55% > 18% (prev 41.99%; Δ 0.55% > 0.5%) |
| Asset Turnover: 56.44% > 50% (prev 58.95%; Δ -2.51% > 0%) |
| Interest Coverage Ratio: 5.51 > 6 (EBIT TTM 2.40b / Interest Expense TTM 435.0m) |
| A: 0.04 (Total Current Assets 9.98b - Total Current Liabilities 8.53b) / Total Assets 37.1b |
| B: 0.15 (Retained Earnings 5.65b / Total Assets 37.1b) |
| C: 0.07 (EBIT TTM 2.40b / Avg Total Assets 35.4b) |
| D: 0.41 (Book Value of Equity 10.7b / Total Liabilities 26.2b) |
| Altman-Z'' = 1.64 = BB |
| DSRI: 1.08 (Receivables 4.74b/4.35b, Revenue 20.0b/19.8b) |
| GMI: 0.99 (GM 41.99% / 42.55%) |
| AQI: 1.02 (AQ_t 0.65 / AQ_t-1 0.64) |
| SGI: 1.01 (Revenue 20.0b / 19.8b) |
| TATA: -0.01 (NI 1.50b - CFO 2.03b) / TA 37.1b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of June 28, 2026, the stock is trading at USD 65.76 with a total of 4,860,842 shares traded. Over the past week, the price has changed by +6.77%, over one month by +2.46%, over three months by -8.03% and over the past year by -12.00%.
Current recommended Stop Loss: 61.70 (which is 6.2% or 2.1 ATR below the current price).
GE HealthCare Technologies has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy GEHC.
- StrongBuy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 79.7 | 21.2% |
P/E Trailing = 14.7698
P/E Forward = 12.6263
P/S = 1.3355
P/B = 2.6262
P/EG = 1.7408
Revenue TTM = 20.0b USD
EBIT TTM = 2.40b USD
EBITDA TTM = 3.40b USD
Long Term Debt = 10.1b USD (from longTermDebt, last quarter)
Short Term Debt = 139.0m USD (from shortTermDebt, last quarter)
Debt = 11.0b USD (from shortLongTermDebtTotal, last quarter) + Leases 443.0m
Net Debt = 8.73b USD (calculated: Debt 11.0b - CCE 2.29b)
Enterprise Value = 36.8b USD (28.0b + Debt 11.0b - CCE 2.29b)
Interest Coverage Ratio = 5.51 (Ebit TTM 2.40b / Interest Expense TTM 435.0m)
EV/FCF = 24.18x (Enterprise Value 36.8b / FCF TTM 1.52b)
FCF Yield = 4.14% (FCF TTM 1.52b / Enterprise Value 36.8b)
FCF Margin = 7.62% (FCF TTM 1.52b / Revenue TTM 20.0b)
Net Margin = 7.54% (Net Income TTM 1.50b / Revenue TTM 20.0b)
Gross Margin = 42.55% ((Revenue TTM 20.0b - Cost of Revenue TTM 11.5b) / Revenue TTM)
Gross Margin QoQ = 38.53% (prev 54.34%)
Tobins Q-Ratio = 0.99 (Enterprise Value 36.8b / Total Assets 37.1b)
Interest Expense / Debt = 3.95% (Interest Expense 435.0m / Debt 11.0b)
Taxrate = 22.41% (440.0m / 1.96b)
NOPAT = 1.86b (EBIT 2.40b * (1 - 22.41%))
Current Ratio = 1.17 (Total Current Assets 9.98b / Total Current Liabilities 8.53b)
Debt / Equity = 1.03 (Debt 11.0b / totalStockholderEquity, last quarter 10.7b)
Debt / EBITDA = 2.57 (Net Debt 8.73b / EBITDA 3.40b)
Debt / FCF = 5.75 (Net Debt 8.73b / FCF TTM 1.52b)
Total Stockholder Equity = 10.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.26% (Net Income 1.50b / Total Assets 37.1b)
RoE = 14.77% (Net Income TTM 1.50b / Total Stockholder Equity 10.2b)
RoCE = 11.81% (EBIT 2.40b / Capital Employed (Equity 10.2b + L.T.Debt 10.1b))
RoIC = 6.71% (NOPAT 1.86b / Invested Capital 27.7b)
WACC = 8.04% (E(28.0b)/V(39.0b) * Re(10.0%) + D(11.0b)/V(39.0b) * Rd(3.95%) * (1-Tc(0.22)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -18.16 | Cagr: -0.10%
[DCF] Terminal Value 76.73% ; FCFF base≈1.46b ; Y1≈1.60b ; Y5≈2.00b
[DCF] Fair Price = 48.07 (EV 30.6b - Net Debt 8.73b = Equity 21.9b / Shares 454.9m; r=8.35% [WACC [floored]]; 5y FCF grow 10.63% → 2.50% )
EPS Correlation: 80.14 | EPS CAGR: 6.70% | SUE: -0.56 | # QB: 0
Revenue Correlation: 82.77 | Revenue CAGR: 1.51% | SUE: 1.19 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.03 | Chg30d=-0.26% | Revisions=-78% | Analysts=13
EPS next Quarter (2026-09-30): EPS=1.24 | Chg30d=-0.33% | Revisions=-25% | Analysts=13
EPS current Year (2026-12-31): EPS=4.87 | Chg30d=-0.21% | Revisions=-83% | GrowthEPS=+6.2% | GrowthRev=+5.6%
EPS next Year (2027-12-31): EPS=5.36 | Chg30d=-0.31% | Revisions=-74% | GrowthEPS=+10.1% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: -83%